Gilead Sciences Inc
Research Gilead Sciences Inc (GILD) on Bullrun: market cap USD 184.62B, dividend yield 2.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGILD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Market capUSD 184.62B
- Dividend yield2.2%
- Financial periodQ2 2026
- RevenueUSD 7.80B
- Net income-USD 10.50B
- Free cash flowUSD 3.43B
- Gross margin79.8%
Valuation Snapshot
latest market cap is USD 184.62B; dividend yield is 2.2%.
Peer valuation comparison
Latest dividend yield is 2.16% versus a Healthcare sector median of 2.11% (2.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 29.44B | USD 8.51B | USD 9.46B | 78.8% | 6.78 | USD 7.56B | USD 24.94B | USD 22.70B |
| FY2024 | USD 28.75B | USD 480.00M | USD 10.31B | 78.3% | 0.38 | USD 9.99B | USD 26.71B | USD 19.33B |
| FY2023 | USD 27.12B | USD 5.67B | USD 7.42B | 76.0% | 4.5 | USD 6.09B | USD 24.99B | USD 22.83B |
| FY2022 | USD 27.28B | USD 4.59B | USD 8.34B | 79.3% | 3.64 | USD 5.41B | USD 25.23B | USD 21.24B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 184.62B | n/a | 2.2% | 3.22 |
| 2025 | 2025-12-31 | USD 152.28B | 18.1 | 2.6% | 3.16 |
| 2024 | 2024-12-31 | USD 115.12B | 249.6 | 3.3% | 3.08 |
| 2023 | 2023-12-29 | USD 100.94B | 17.4 | 3.7% | 3 |
| 2022 | 2022-12-30 | USD 107.68B | 32.5 | 3.4% | 2.92 |
| 2021 | 2021-12-31 | USD 91.05B | 14.7 | 3.9% | 2.84 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 3.22 USD, yield 2.2%.
| Year | Dividends/share |
|---|---|
| FY2025 | 3.16 USD |
| FY2024 | 3.08 USD |
| FY2023 | 3 USD |
| FY2022 | 2.92 USD |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gilead Sciences Inc's market cap?
Gilead Sciences Inc's market capitalization is USD 184.62B.
Does Gilead Sciences Inc pay a dividend?
Gilead Sciences Inc has a dividend yield of 2.2%.
What does Gilead Sciences Inc do?
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.